No Effect of Omega-3 Fatty Acid Supplementation on Cognition and Mood in Individuals with Cognitive Impairment and Probable Alzheimer’s Disease: A Randomised Controlled Trial

International Journal of Molecular Sciences

Michelle A. Phillips³  Caroline E. Childs¹  Philip C. Calder¹  Peter J. Rogers³  Cenk Suphioglu² 

[1]Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK

[2] E-Mails:

[3]School of Experimental Psychology, University of Bristol, Bristol BS8 1TU, UK

[4] E-Mail

[5]School of Experimental Psychology, University of Bristol, Bristol BS8 1TU, UK

[6] E-Mail:

关键词: Alzheimer’s disease (AD);    cognitive impairment no dementia (CIND);    omega-3 fatty acids;    eicosapentaenoic acid (EPA);    docosahexaenoic acid (DHA);   

DOI  :  10.3390/ijms161024600

来源: mdpi

【 摘 要 】

Findings from epidemiological and observational studies have indicated that diets high in omega-3 polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) may reduce the risk of cognitive decline and Alzheimer’s disease (AD). To determine if increasing intake of DHA and EPA through supplementation is beneficial to cognition and mood in individuals with cognitive impairment no dementia (CIND) or Alzheimer’s disease (AD) a four month, randomised, double-blind, placebo controlled study was conducted. Fifty-seven participants with CIND and nineteen with AD were randomised to receive either omega-3 PUFAs (600 mg EPA and 625 mg DHA per day) or placebo (olive oil) over a four month period. Elevating depleted levels of EPA and DHA through supplementation in individuals with CIND or AD was found to have negligible beneficial effect on their cognition or mood. These findings confirm an overall negligible benefit of omega-3 PUFA supplementation for those with cognitive impairment and dementia. More intervention studies need to be undertaken with longer study durations and larger sample sizes. It may prove fruitful to examine effects of different doses as well as effects in other dementia subtypes.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.